FibroGen to Announce Financial Performance
FibroGen, Inc. (NASDAQ: FGEN), a prominent biopharmaceutical firm, is preparing to unveil its financial results for the fourth quarter and the full year of 2024. The announcement is set for Monday, March 17, taking place after the market closes. This session will provide a comprehensive overview of the company’s financial standing and corporate advancements.
Insights from the Conference Call
Following the financial report, FibroGen will conduct a conference call scheduled for 5:00 PM Eastern Time. This call is an opportunity for the management team to delve deeper into the financial outcomes and discuss the company’s future direction. Participants will have the opportunity to engage in a live Q&A session following the main presentation, making it an interactive experience for stakeholders.
Accessing the Call
Investors and interested parties can listen to the conference call through a live audio webcast. To access this, registration is required. The call can also be accessed via phone, with dial-in details provided upon registration. Following the live event, a replay will be offered on FibroGen’s website for a limited duration, ensuring that those unable to attend the live session can still gain valuable insights.
About FibroGen
FibroGen, Inc. focuses on pioneering therapies in the challenges of cancer biology and anemia treatment. The company’s flagship product, Roxadustat (also known as EVRENZO™), has garnered regulatory approvals in various regions, including China, Europe, and Japan, specifically for treating anemia in patients with chronic kidney disease (CKD), both on dialysis and not. FibroGen is also exploring additional applications for Roxadustat in conditions like lower-risk myelodysplastic syndrome (LR-MDS).
Innovative Treatments Under Development
Moreover, FibroGen is advancing FG-3246 (or FOR46), a groundbreaking antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer treatment. This innovative approach showcases FibroGen's commitment to addressing unmet medical needs in oncology and related fields, and it also encompasses the development of FG-3180, a CD46-targeted PET biomarker.
Stay Updated with FibroGen
For more detailed information about the company’s advancements and to access the latest updates regarding their therapies, interested individuals can visit FibroGen’s official website. This platform serves as a hub for learning about ongoing clinical trials and any new announcements pertaining to their product pipeline.
Frequently Asked Questions
What financial results will FibroGen announce?
FibroGen will announce its fourth quarter and full year 2024 financial results, offering insights into its corporate performance.
When is the conference call scheduled?
The conference call is scheduled for March 17 at 5:00 PM Eastern Time, following the financial results announcement.
How can I listen to the conference call?
Investors can access the conference call through a live audio webcast, with phone access available after registering in advance.
What is Roxadustat?
Roxadustat is FibroGen's primary product, approved for treating anemia in chronic kidney disease patients across multiple countries.
What other treatments is FibroGen developing?
FibroGen is also working on FG-3246, an ADC for prostate cancer, and FG-3180, a PET biomarker targeting CD46.
